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Age-related osteoporosis is characterized by
reduced bone formation and accumulation of fat in
the bone marrow compartment. Here, we report
that the type 1 cannabinoid receptor (CB1) regulates
this process. Mice with CB1 deficiency (CB1/) had
increased peak bone mass due to reduced bone
resorption, but developed age-related osteoporosis
with reduced bone formation and accumulation of
adipocytes in the bone marrow space. Marrow
stromal cells from CB1/ mice had an enhanced
capacity for adipocyte differentiation, a reduced
capacity for osteoblast differentiation, and increased
expression of phosphorylated CREB (pCREB) and
PPARg. Pharmacological blockade of CB1 receptors
stimulated adipocyte differentiation, inhibited osteo-
blast differentiation, and increased cAMP and
pCREB in osteoblast and adipocyte precursors.
The CB1 receptor is therefore unique in that it regu-
lates peak bone mass through an effect on osteo-
clast activity, but protects against age-related bone
loss by regulating adipocyte and osteoblast differen-
tiation of bone marrow stromal cells.
INTRODUCTION
Osteoporosis is a common disease characterized by reduced
bone mineral density (BMD) and increased risk of fragility frac-
tures. Osteoporosis becomes progressively more common
with increasing age as the result of bone loss (Raisz, 2005).
Women undergo a phase of rapid bone loss immediately after
menopause due to estrogen deficiency, which increases bone
turnover and causes uncoupling of bone resorption and bone
formation (Riggs et al., 1982). Subsequently, bone turnover falls,
but bone loss continues, because the amount of bone that is
removed by osteoclasts exceeds that which can be replaced
by osteoblasts during the bone remodeling cycle (Lips et al.,
1978; Eriksen et al., 1985). This age-related reduction in osteo-
blast activity is due in part to the fact that bone marrow stromalCecells (MSCs) from elderly subjects have a reduced capacity to
differentiate into osteoblasts and an increased capacity to differ-
entiate into adipocytes, which leads to progressive accumula-
tion of fat in the bonemarrow space with increasing age (Meunier
et al., 1971; Verma et al., 2002; Justesen et al., 2001, 2002; Cao
et al., 1991; Gimble et al., 2006).
Lineage commitment of MSCs is critically dependent on acti-
vation of the cyclic AMP/CREB pathway, which downregulates
expression of the osteoblast-specific transcription factor Cbfa1
(Tintut et al., 1999) and upregulates expression of the adipo-
cyte-specific transcription factors C/EBPb and PPARg (Cao
et al., 1991; Reusch et al., 2000; Fox et al., 2006; Yang et al.,
2008). Glucocorticoids, insulin, thiazolidinediones, and agents
that elevate intracellular cAMP can all initiate adipogenesis
in vitro, but the mechanisms by which adipogenesis is regulated
in vivo remain poorly understood (Fox et al., 2006). In this study,
we investigated the hypothesis that the type 1 cannabinoid
receptor (CB1) might be involved in this process.
Cannabinoid receptors belong to the G protein-coupled
receptor superfamily and employ Gi/o proteins to regulate cAMP
levels and other intracellular signaling pathways in target cells.
Cannabinoid receptor agonists such as CP55,490 bind to canna-
binoid receptorsand inhibit cAMPproduction (DemuthandMolle-
man, 2006), whereas antagonists such as AM251 block these
effects. Most cannabinoid receptor antagonists can activate
signaling in the absence of agonist binding with opposite effects
on cAMP and other signaling pathways to those of agonists and
hence are classified as inverse agonists (Pertwee, 1999). Recent
studies have shown that both the type 1 (CB1) and type 2 (CB2)
cannabinoid receptors play distinct roles in regulating bone
mass and bone turnover (Idris et al., 2005, 2008b; Ofek et al.,
2006), but neither receptor hasbeen implicated in regulatingoste-
oblast and adipocyte differentiation of MSCs. Here, we show that
the CB1 pathway plays a critical role in this process and in so
doing protects against age-related bone loss.
RESULTS
CB1/ Mice Have Increased Peak Bone Mass,
but Develop Age-Related Osteoporosis
Male and female CB1/ mice had increased trabecular bone
mass at 3 months, as assessed by micro-CT analysis of the tibialll Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Inc. 139
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CB1 Regulates Marrow Stromal Cell DifferentiationFigure 1. Mice with CB1 Deficiency Have Increased Peak Bone Mass, but Develop Age-Related Osteoporosis with Accumulation of Marrow
Fat
(A) Changes in trabecular BV/TV with age in male wild-type and CB1/ mice. Values are mean ± SEM from 6–8 mice per group (**p < 0.01, *p < 0.05 between
genotypes).
(B) Representative micro-CT scans from 3-month-old and 12-month-old male mice.
(C) Representative photomicrographs of the tibial metaphysis from 12-month-old male mice.
(D) Changes in trabecular bone volume with age in female wild-type and CB1/ mice. Values are mean ± SEM from 6–8 mice per group (**p < 0.01, *p < 0.05
between genotypes).
(E) Representative micro-CT scans from 3-month-old and 12-month-old female mice.140 Cell Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Inc.
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CB1 Regulates Marrow Stromal Cell DifferentiationTable 1. Bone Histomorphometry and Biochemical Markers of Bone Turnover in CB1/ and Wild-Type Mice
Act.Res/BS
(%)
Oc.N/BS
(cells/mm)
Ob.N/BS
(cells/mm)
Adipo/SA
(%)
MAR
(mm/day)
BFR/BS
(mm/day)
P1NP
(ng/ml)
CTX
(ng/ml)
Female Wild-type (3 months) 8.6 ± 0.8 3.5 ± 0.5 15.1 ± 1.2 0.89 ± 0.2 5.9 ± 0.2 3.5 ± 0.2 21.4 ± 1.6 36.4 ± 1.1
CB1/ (3 months) 4.1 ± 0.4*** 1.6 ± 0.2* 14.0 ± 1.6 0.83 ± 0.1 6.5 ± 0.4 3.2 ± 0.4 24.5 ± 2.3 26.6 ± 3.9**
Wild-type (12 months) 2.9 ± 3.1 0.13 ± 0.14 1.35 ± 1.1 17.6 ± 8.5 2.3 ± 0.3 1.1 ± 0.2 11.8 ± 1.1 28.8 ± 1.6
CB1/ (12 months) 0.3 ± 0.5* 0.01 ± 0.02* 0.61 ± 0.47* 76.3 ± 17.3** 1.0 ± 0.2** 0.43 ± 0.1** 6.0 ± 0.8** 25.6 ± 2.3
Male Wild-type (3 months) 2.1 ± 0.3 0.90 ± 0.1 3.1 ± 0.3 0.55 ± 0.07 6.2 ± 0.2 3.0 ± 0.3 25.3 ± 2.5 31.4 ± 2.3
CB1/ (3 months) 0.8 ± 0.07** 0.30 ± 0.04* 2.8 ± 0.4 0.67 ± 0.01 6.7 ± 0.3 2.5 ± 0.3 21.8 ± 0.9 23.7 ± 2.1**
Wild-type (12 months) 0.7 ± 0.1 0.30 ± 0.07 1.8 ± 0.4 2.66 ± 0.8 4.6 ± 0.3 1.9 ± 0.3 10.6 ± 0.4 27.8 ± 2.8
CB1/ (12 months) 0.08 ± 0.01* 0.02 ± 0.01* 0.7 ± 0.1** 56.8 ± 19.3** 1.3 ± 0.1** 0.56 ± 0.08** 4.9 ± 0.6** 18.8 ± 1.6**
Values are means ± SEM and are obtained from 6–8 animals per group, with the exception of P1NP in 12-month-old wild-type mice, where only 4
samples were available for analysis (* p < 0.05, **p < 0.01, ***p < 0.001, wild-type versus CB1/ mice of the same age).
Act.Res/BS, active resorption surface/bone surface; Oc.N/BS, osteoclast number/bone surface; Ob.N/BS, osteoblast number/bone surface; Adipo/
SA, adipocyte area/section area; MAR, mineral apposition rate; BFR/BS, bone formation rate/bone surface.metaphysis, when compared with wild-type littermates (Figures
1A–1E). Bone histomorphometry showed that active resorption
surface and osteoclast numbers were significantly reduced in
male and female CB1/ mice at this age when compared with
wild-type, whereas no differences were observed in osteoblast
number, mineral apposition rate (MAR), or bone formation rate
(BFR) (Table 1). In keeping with these observations, serum levels
of the bone resorption marker C-terminal telopeptide crosslinks
(CTX) were reduced in 3-month-old CB1/mice compared with
wild-type, whereas levels of the N-terminal propeptide of type 1
procollagen (P1NP), a bone formation marker, were not signifi-
cantly different (Table 1). These findings indicate that the likely
mechanism for the increased trabecular bone mass in CB1/
mice is a relative reduction in osteoclast activity in the face of
normal osteoblast activity, causing a positive balance in favor
of bone formation during skeletal growth. In order to define the
mechanisms responsible for the reduced osteoclast activity,
we studied osteoclast differentiation in CB1/ mice and wild-
type controls using osteoblast-bone marrow cocultures and
receptor activator of nuclear factor kappa B ligand (RANKL)-
stimulated bone marrow macrophage cultures. Osteoclast
formation was significantly reduced in cocultures prepared
from CB1/ mice when compared with wild-type mice, but
this was largely rescued by culture of CB1/ marrow cells
with wild-type osteoblasts (Figure 1G). This indicates that CB1
deficiency impairs the ability of osteoblasts to support osteo-
clast formation. Since osteoclast formation is critically depen-
dent on RANKL expressed by osteoblasts (Kong et al., 1999),
we studied RANKL expression by quantitative PCR in osteoblast
cultures and found that RANKL mRNA levels were significantly
lower in CB1/ cultures than in wild-type cultures (1584 ± 117
copies versus 2041 ± 140 copies; p < 0.01). Resorption pitCeformation was also reduced in cocultures from CB1/ mice as
compared with wild-type (Figure 1I), in keeping with the reduc-
tion in osteoclast numbers (representative photomicrographs,
Figure 1J). We also found that RANKL- and macrophage colony
stimulating factor (M-CSF)-induced osteoclast formation was
reduced in bone marrow macrophage cultures from CB1/
mice as compared with wild-type (Figure 1H; representative
photomicrographs, Figure 1K). Taken together, these observa-
tions demonstrate that CB1 regulates osteoclast differentiation
both directly, by negatively impacting on the ability of osteoclast
precursors to respond to M-CSF and RANKL, and indirectly, by
modulating expression of RANKL by osteoblast-like cells.
Although CB1/mice of both genders had increased trabec-
ular bone mass at 3 months of age when compared with wild-
type, they developed osteoporosis with increasing age (Figures
1A–1F). In male CB1/ mice, trabecular bone volume/tissue
volume (BV/TV) fell by a mean (± SEM) of 54% ± 6.3% compared
with a 3.7% ± 10.1% gain in wild-type littermates (p < 0.001).
Similarly, BV/TV fell by 64.6% ± 3.7% in female CB1/ mice
compared with a 37.1% ± 9.4% fall in wild-type littermates
(p < 0.01). Analysis of trabecular bone by micro-CT at lumbar
vertebra 5 showed a pattern similar to that observed at the tibial
metaphysis, with higher BV/TV values at 3 months in CB1/
mice, but lower values at 12 months (data not shown). Histolog-
ical analysis of the tibial metaphysis in 12-month-old mice
showed that the osteoporosis in CB1/ mice was associated
with a striking increase in accumulation of adipocytes in the
bonemarrow compartment (Figures 1C and 1F). This was partic-
ularly evident in females, where the bone marrow space was
almost completely replaced with adipocytes. Analysis of bone
histomorphometry in 12-month-old mice showed evidence of
reduced bone turnover in both CB1/ and wild-type, but(F) Representative photomicrographs of the tibial metaphysis from 12-month-old female mice.
(G) Bone marrow osteoblast cocultures in CB1/ and wild-type mice. Values are mean ± SEM and are representative of three independent experiments
(**p < 0.01 from wild-type cultures).
(H) RANKL- and M-CSF-generated osteoclast formation from CB1/ and wild-type mice. Values are mean ± SEM and are representative of three independent
experiments (**p < 0.01, *p < 0.05 between genotypes).
(I) Resorption pit formation in bone marrow osteoblast cocultures from CB1/ and wild-type mice. Values are mean ± SEM and are representative of three
independent experiments (**p < 0.01, between genotypes).
(J) Photomicrographs of dentine slices from cocultures in CB1/ and wild-type mice.
(K) Representative photomicrographs of osteoclast cultures from CB1/ and wild-type mice.ll Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Inc. 141
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CB1 Regulates Marrow Stromal Cell Differentiationosteoclast numbers, active resorption surfaces, osteoblast
number, MAR, and BFR were all significantly lower in CB1/
compared with wild-type, and adipocyte area was greatly
increased (Table 1). Serum levels of P1NP and CTX were also
lower in CB1/ mice compared with wild-type at 12 months,
but the difference between genotypeswas not statistically signif-
icant for CTX in female mice. These data demonstrate that the
age-related osteoporosis in CB1/ mice of both genders is
associated with low turnover with a reduction in bone formation
and accumulation of bone marrow fat.
The CB1 Pathway Regulates Osteoblast
and Adipocyte Differentiation in Bone MSCs
In order to investigate the mechanisms underlying the reduced
bone formation and increased fat accumulation in CB1/
mice, we studied osteoblast and adipocyte differentiation in
MSC cultures prepared from CB1/ and wild-type mice.
MSCs from CB1/ mice had a significantly reduced capacity
to form mineralized bone nodules when cultured in osteogenic
medium (Figures 2A and 2B). Similar results were obtained
whether the cultures were performed using cells derived from
3-, 6-, and 12-month old mice (data not shown). Bone nodule
formation was inhibited by pharmacological blockade of CB1
receptors with AM251 (Figures 2C and 2D), but was stimulated
by CP55,490, a nonselective cannabinoid receptor agonist
(Figures 2E and 2F). Further studies showed that CB1/
MSCs had an enhanced ability to differentiate into adipocytes
when cultured in adipogenic medium (Figures 2G and 2H) and
showed increased expression of the adipogenic transcription
factors PPARg and phosphorylated cAMP response element-
binding factor (pCREB) compared with wild-type (Figure 2I).
Moreover, the stimulatory effect of AM251 on adipocyte differen-
tiation could be reversed by the cannabinoid receptor agonist
CP55,490 and the Gi/o inhibitor pertussis toxin (Figures 2J and
2K). Taken together, these data indicate that signaling through
the CB1 receptor regulates the ability of bone MSCs to differen-
tiate into adipocytes in vitro and are consistent with a model
whereby deficiency of CB1 predisposes to osteoporosis by
reciprocally regulating adipocyte and osteoblast differentiation
in the bone marrow compartment in vivo.
Cannabinoid Ligands Regulate cAMP
and CREB in Preadipocytes and Osteoblast-like Cells
Since cAMP and CREB play important roles in regulating adipo-
cyte differentiation in vitro (Fox et al., 2006), we wanted to deter-
mine if CB1 signaling modulates cAMP and CREB phosphoryla-
tion in preadipocytes and osteoblast-like cells. The cannabinoid
receptor agonist CP55,490 inhibited forskolin-induced cAMP
accumulation in 3T3-L1 preadipocytes, and this was reversed
by AM251 and the Gi/o inhibitor pertussis toxin (Figure 3A).
Further studies showed that AM251 increased pCREB in 3T3-
L1 cells, but had no effect on levels of the related transcription
factor ATF1 and no consistent effect on total CREB (Figure 3B).
In MC3T3 cells, we observed similar effects of CP55,490,
pertussis toxin, andAM251on cAMP levels (Figure 3C) and found
that AM251 increased pCREB and, to a lesser extent, ATF-1, but
had no effect on total CREB (Figure 3D). Taken together, these
data indicate that signaling through the CB1 receptor regulates
cAMP levels and CREB phosphorylation in preadipocytes and142 Cell Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Incosteoblast-like cells, providing an explanation for the enhance-
ment of adipocyte differentiation and reduction in bone nodule
formation, which we observed in MSC cultures from CB1/
mice.
Expression of CB1 in the Bone Microenvironment
Increases with Age
While CB1 is highly expressed in the brain, it is also widely ex-
pressed in peripheral tissues (Howlett et al., 2002). Since the
in vitro studies that we performed showed that CB1 exerts direct
effects on bone cells, we studied levels of CB1 expression in the
bone microenvironment by quantitative PCR and looked for
evidence of possible changes in CB1 expression with age in
view of the dramatic effect of age on the skeletal phenotype in
CB1/ mice. These studies showed that the mRNA levels for
CB1 were highest in the brain, but were also clearly detectable
in several other cell types in the periphery, includingMSCs, oste-
oblasts, osteoclasts, bone marrow macrophages, spleen, and
adipocytes (Figure 3E). There also was a significant increase in
levels of CB1 transcript between 3 and 12 months of age in
freshly isolated bone marrow cells from wild-type mice
(Figure 3F), demonstrating that CB1 expression is upregulated
with age in the bone marrow compartment, providing a possible
explanation for the age-related effects of CB1 deficiency on
bone loss and marrow fat accumulation.
DISCUSSION
The observations presented here demonstrate that the CB1
pathway plays a unique role in bone metabolism by regulating
peak bone mass through effects on osteoclastogenesis and
bone resorption and age-related bone loss through effects on
differentiation of MSCs. Mice with CB1 deficiency had signifi-
cantly increased trabecular bone mass at 3 months of age
when compared with wild-type littermates, and levels of osteo-
clastic bone resorption were reduced. Bone marrow macro-
phages from CB1/ mice were less responsive to RANKL and
M-CSF than wild-type, and CB1/ osteoblasts were less able
to support osteoclast formation and expressed lower amounts
of RANKL. Since bone formation in 3-month-old CB1/ mice
was similar to that ofwild-type, this indicates that the high trabec-
ular bonemass thatweobservedwasprimarily due to a reduction
in bone resorption in the presence of normal bone formation. The
high peak bonemass reported here is in keepingwith the findings
of Tam and colleagues, who reported that 3-month-old CB1/
mice on a CD1 genetic background had high trabecular bone
mass, although the difference was statistically significant only
for males (Tam et al., 2008). It should be noted, however, that in
Tam’s study,CB1/mice on aC57BL/6 backgroundwere found
to have low bone mass. The reason for the difference between
strains is unclear, although it might be partly related to the fact
that, among common inbred strains, C57BL/6 mice have the
lowest femoral volumetric bone density and femoral trabecular
bone volume (Beamer et al., 1996). It could be that C57BL/6
mice harbor recessive mutations in pathways that abrogate or
modify the effects of the CB1 pathway on bone cell activity or
that CB1/ mice on a CD1 background have a distinct skeletal
phenotype because of epistatic interactions with polymorphisms
in other genes..
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CB1 Regulates Marrow Stromal Cell DifferentiationFigure 2. The CB1 Pathway Regulates Osteoblast and Adipocyte Differentiation In Vitro
(A) Bone nodule formation in MSC cultures from CB1/ and wild-type mice. Values are mean ± SEM and are representative of three independent experiments
(**p < 0.01 between genotypes).
(B) Representative photomicrographs from the cultures shown in (A).
(C) Bone nodule formation in MSC cultures fromwild-typemice in the presence or absence of AM251 (100 nM). Values are mean ± SEM and are representative of
three independent experiments (**p < 0.01 between genotypes).
(D) Representative photomicrographs from the cultures shown in (C).
(E) Bone nodule formation in MSC cultures from wild-type mice in the presence or absence of CP55,490 (CP55; 100 nM). Values are mean ± SEM and are repre-
sentative of three independent experiments (**p < 0.01 between genotypes).
(F) Representative photomicrographs from the cultures shown in (E).
(G) Adipocyte formation in MSC cultures from CB1/ and wild-type mice grown in adipogenic medium in the presence and absence of AM251 (100 nM). Values
are means ± SEM and are representative of at least three independent experiments (**p < 0.01 between genotypes; ##p < 0.01 vehicle versus AM251).
(H) Representative photomicrographs from the cultures shown in (G). Adipocytes are the cells with accumulation of yellow/white lipid droplets in the cytoplasm.
(I) Expression of PPARg and pCREB in the cultures shown in (G), assessed by western blotting.
(J) Adipocyte formation in wild-type MSCs cultured in adipogenic medium stained with Nile red O and treated with AM251, pertussis toxin (PTX; 20 ng/ml), and
CP55,490.
(K) Representative photomicrographs from the cultures shown in (J).While peak bone mass was initially higher in CB1/ mice,
greater amounts of bone were lost with increasing age when
compared with wild-type. Accordingly, levels of trabecularCebone mass were similar in 6-month-old CB1/ mice and wild-
type controls, whereas by 12 months, CB1/ mice had devel-
oped marked osteoporosis, with replacement of the bonell Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Inc. 143
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CB1 Regulates Marrow Stromal Cell DifferentiationFigure 3. Cannabinoids Regulate cAMP Signaling and CREB Phosphorylation in Adipocytes and Osteoblasts
(A) Effects of CP55,490 (CP55; 100 nM), AM251 (100 nM), forskolin (FSK; 10 mM), and pertussis toxin (PTX; 20 ng/ml) on cAMP levels in 3T3-L1 preadipocytes.
Levels of cAMP are in arbitrary units derived from incorporation of [3H] to cAMP in relation to total [3H]adenine-containing nucleotides. Values are mean ± SEM
and are representative of three independent experiments (**p < 0.01, FSK versus other groups).
(B) Effect of AM251 on total CREB, pCREB, and ATF1 in 3T3-L1 preadipocyte cultures, assessed by western blotting.
(C) Effects of CP55,490 (CP55; 100 nM), AM251 (100 nM), forskolin (FSK; 10 mM) and pertussis toxin (PTX; 20 ng/ml) on cAMP levels in MC3T3 osteoblast-like
cells. Level of cAMP are in arbitrary units derived from incorporation of [3H] to cAMP in relation to total [3H]adenine-containing nucleotides. Values are mean ±
SEM and are representative of three independent experiments (*p < 0.05, FSK versus other groups).
(D) Effect of AM251 on total CREB, pCREB, and ATF1 in MC3T3 osteoblast-like cell, assessed by western blotting.
(E) Expression of CB1 mRNA assessed by quantitative PCR and expressed as the number of molecules per nanogram of total RNA in various cells and tissues.
(F) Expression of CB1mRNA in freshly isolated bonemarrow cells frommice aged 3 and 12months (***p < 0.01 between groups; MSC, bonemarrow stromal cell;
OB, osteoblast; MF, macrophage; OCL, osteoclast).marrow compartment by adipocytes. This was particularly
evident in females, but was also observed in males. Histomor-
phometric analysis showed that levels of bone turnover were
reduced at 12 months of age when compared with 3 months in
both CB1/ and wild-type mice, but the reduction in bone
formation was significantly greater in CB1/ mice when com-144 Cell Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Inpared with wild-type. Although histomorphometric indices of
bone resorption were also lower in 12-month-old CB1/ mice
as compared with wild-type, the reduction in bone formation
was clearly more profound than the reduction in bone resorption,
reflected by the fact that both male and female CB1/ mice
developed osteoporosis with increasing age.c.
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CB1 Regulates Marrow Stromal Cell DifferentiationIn keeping with the findings in vivo, we found that MSCs from
CB1/ mice had an impaired ability to differentiate into osteo-
blasts, but an increased ability to differentiate into adipocytes
in vitro. These differences in lineage commitment were accom-
panied by reduced expression of Cbfa1, which promotes osteo-
blast differentiation, and increased expression of pCREB and
PPARg, which promote adipocyte differentiation. Raised intra-
cellular levels of cAMP are known to stimulate adipocyte differ-
entiation in vitro by promoting CREB phosphorylation, which in
turn increases expression of the adipocyte-specific transcription
factorsC/EBPb, PPARg, andC/EBPa (Fox et al., 2006; Yanget al.,
2008). Conversely, increased levels of cAMP in preosteoblasts
inhibit osteoblast differentiation by reducing Cbfa1 expression
and Cbfa1-DNA binding (Tintut et al., 1999). In this study, the
cannabinoid receptor agonist CP55,490 inhibited forskolin-
induced cAMP accumulation in 3T3-L1 cells, and this effect
was reversed by the CB1 selective inverse agonist AM251 and
theGi/o inhibitor pertussis toxin.Moreover, the stimulatory effect
of AM251 on adipocyte differentiation of mesenchymal stem
cells was abrogated by pertussis toxin, which is known to block
receptor-mediated regulation of the Gi/o protein (Yajima et al.,
1986), illustrating that CB1 regulates adipocyte differentiation
by a Gi/o-mediated pathway. Similar responses were observed
in MC3T3 osteoblast-like cells, suggesting that CB1 also regu-
lates osteoblast differentiation by a cAMP-dependent pathway.
Taken together, these observations are consistent with a model
whereby CB1 deficiency increases cAMP levels in mesenchymal
stromal cells, leading to CREB phosphorylation and increased
PPARg expression, thereby enhancing adipocyte differentiation
at the expense of osteoblast differentiation. In accordance with
this view, the skeletal phenotype observed in aged CB1/
mice was, in many respects, similar to that reported in mice
that have been treated with rosiglitazone, which directly acti-
vates PPARg to increase adipocyte differentiation and inhibit
osteoblast differentiation (Ali et al., 2005; Rzonca et al., 2004).
It is of interest that the reduced bone formation and increased
marrow fat accumulation was observed only in aged CB1/
mice, even though MSCs cultured from CB1/ mice of all
ages had a reduced ability to differentiate into osteoblasts and
an increased ability to differentiate into adipocytes in vitro. This
suggests that in young mice, other signaling pathways can
compensate for the effects of CB1 deficiency in vivo and main-
tain normal bone formation. With increasing age, however, these
compensatory mechanisms clearly fail, leading to the defect in
bone formation and increase in marrow fat accumulation that
we observed in agedmice. Further research will now be required
to identify these pathways and the mechanisms by which they
interact with CB1 deficiency to influence MSC differentiation
in vivo. One such factor might be levels of CB1 expression, since
we observed a 25% increase in CB1 expression in bone marrow
of wild-type mice between 3 and 12 months, raising the possi-
bility that there is physiological upregulation of CB1 expression
with age, which protects against the development of osteopo-
rosis.
Since the CB1 receptor is known to play a role in energy
metabolism, we considered the possibility that the changes in
marrow fat distribution might have been related to generalized
changes in fat metabolism. In this regard, previous studies
have shown that CB1/mice are leaner than wild-type controls,Cedue in part to the fact that they eat less (Ravinet et al., 2004). The
CB1/mice used in this study had a 3%–7% lower body weight
than wild-type controls, but these differences were constant
throughout life (data not shown). Although we cannot completely
exclude the possibility that redistribution of adipocytes from
peripheral sites to the bone marrow space might have occurred,
this would not explain the reduction in bone formation that we
observed in 12-month-old CB1/ mice or the effects of CB1
on adipocyte and osteoblast differentiation in vitro.
The stimulatory effect of CB1 on osteoblast differentiation that
we found in this study is in keepingwith theobservationsmadeby
Tamandcolleagues,who reported thatCB1acts as amediator of
increased bone formation that follows traumatic brain injury (TBI)
(Tam et al., 2008). In that study, TBI-induced bone formation was
absent inCB1/miceandwasalsoblockedby isoprenaline infu-
sions. This led the authors to speculate that CB1 stimulates bone
formation by inhibiting release of catecholamines fromperipheral
nerves, although in the present study, we observed direct effects
of CB1 on osteoblast differentiation in vitro. While we cannot
exclude the possibility that CB1-regulated neurogenic pathways
may have contributed to the phenotype that we observed, the
present study shows that CB1 exerts cell-autonomous effects
ondifferentiation ofmesenchymal cells to osteoblasts andadipo-
cytes and exerts direct effects on osteoclast differentiation.
Further studies using cell-specific or neuron-specific inactivation
of CB1 will be required to address the relative importance of
central versus peripheral CB1 signaling to the regulation of the
skeletal phenotypes described in this study.
In summary, our studies demonstrate that CB1 plays a unique
role in bonemetabolism by exerting bidirectional effects on bone
mass at different stages in life, bymodulating osteoclast differen-
tiation, and by regulating differentiation ofMSCs into osteoblasts
and adipocytes. This work has important clinical implications in
raising the possibility that cannabinoid receptor ligands may be
of value therapeutically in enhancing peak bonemass and in pre-
venting age-relatedosteoporosis, but indicates that agonists and
antagonists may exert contrasting effects on the skeleton at
different stages in life.
EXPERIMENTAL PROCEDURES
Materials
All reagents were obtained from Sigma (Poole Dorset, UK) unless otherwise
indicated. Culture media were obtained from Invitrogen (Paisley, UK), and anti-
bodies were from Cell Signaling Technology (Danvers, MA), unless otherwise
stated. Cultures were grown in a-MEM supplemented with 10% FCS, 1%
penicillin, 1% streptomycin, and 2 mM glutamine. The cannabinoid receptor
ligands AM251 and CP55,490 were obtained from Tocris Bioscience (Bristol,
UK), dissolved in DMSO, and added to the cell cultures in the concentrations
indicated such that the final concentration of DMSO was 0.1% or less. Control
cultures were treated with DMSO alone at the same concentration.
Animals
Mice with targeted inactivation of CB1were generated by homologous recom-
bination as described previously (Ledent et al., 1999) and were a kind gift from
Dr. Christine Ravinet-Trillou (Sanofi-Aventis; Paris). Heterozygous mice were
bred for at least 17 generations onto a CD1 background before generating
the CB1/ and wild-type littermates used in this study.
Osteoblast Isolation and Culture
Osteoblasts were isolated from the calvarial bones of 2-day-old mice by
sequential collagenase digestion. Prior to experimentation, the cells werell Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Inc. 145
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Osteoblasts were then seeded onto 96-well plates at 8 3 103 cells per well,
48-well plates at 12 3 103 cells per well, or 12-well plates at 60 3 103 cells
per well. Osteoblast numbers were determined by Alamar blue assay accord-
ing to the manufacturer’s instruction. Subsequently, cell extracts were
prepared, and alkaline phosphatase activity was measured and corrected
for cell number previously described (Idris et al., 2008a).
Bone Nodule and Adipocyte Cultures
MSCs from female CB1/ andwild-typemice were seeded into 12-well plates
at 603 103 cells per well in 2ml of a-MEM supplemented with 3mM b-glycerol
phosphate and 50 mg/ml L-ascorbic acid as previously described (Idris et al.,
2008a). The cells were cultured for between 10 and 21 days, with replacement
of the culture medium every 3 days and daily replacement of L-ascorbic acid.
At the end of the cultures, the plates were fixed in 70% cold ethanol, and the
mineralized nodules were visualized by alizarin red staining. Bone nodule
formation was quantitated by destaining the cultures for 15 min in cetylpyridi-
nium chloride and measuring absorbance of the extracted stain by spectro-
photometry as previously described (Stewart et al., 2005). The values were
normalized to cell number as determined by the Alamar blue assay. For the
primary adipocyte cultures, marrow cells were isolated from the long bones
of 3- to 5-month-old mice and seeded into a Petri dish at 1 3 108 cells in
10 ml of standard a-MEM supplemented with insulin (10 mg/ml), with replace-
ment of the culture medium every 2 days until confluence. Adherent cells were
released with trypsin and replated at 104 cells/well in 24-well plates in 500 ml
culture medium supplemented with insulin (10 mg/ml), dexamethasone
(250 nM), indomethacin (100 nM), troglitazone (1 mM), and isobutylmethylxan-
thine (0.5 mM) for 2–4 days in the presence or absence of test factors. At the
end of the culture period, adipocytes were identified morphologically by Nile
red O staining and quantitated by counting six high-powered fields per treat-
ment group. For the preadipocyte 3T3-L1 cultures, cells were seeded into
12-well tissue culture plates at 1 3 105 cells in 1 ml of standard a-MEM sup-
plemented with insulin (1 mg/ml), with replacement of the culture medium every
2 days until confluence.
Bone Marrow Cocultures and Osteoclast Cultures
Bone marrow cells were isolated from the long bones of 3- to 5-month-old
mice and seeded into a Petri dish at 1 3 108 cells in 10 ml of standard
a-MEM. The adherent stromal cells were trypsinized and replated together
with the nonadherent bone marrow cells at 104 cells/well and 2 3 105 cells/
well, respectively, on dentine slices in 96-well plates in 150 ml of standard
a-MEM supplemented with 10 nM 1,25-dihydroxyvitamin D3 for 10 days. For
the RANKL-generated osteoclast cultures, nonadherent bone marrow cells
were cultured in the presence of 100 ng/ml M-CSF (R&D Systems; Abingdon,
UK) for 2 days followed by another 3 days in the presence of 25 ng/ml M-CSF
(R&D Systems) and 100 ng/ml RANKL (a gift from Patrick Mollat, Galapagos;
Romaineville, France), so the total culture time was 5 days. Osteoclasts
were identified by TRAcP staining as described previously (van’t Hof, 2003).
Western Blotting
Cells lysates were prepared using a buffer containing 100 mM Tris-HCl
(pH 7.8), 150 mM NaCl, 0.1% Triton X-100, 5% protease inhibitor cocktail,
and 5% phosphatase inhibitor cocktail. Protein content was determined,
and an identical amount of protein from each extract was analyzed by
SDS-PAGE and transferred to a PVDF membrane (Amersham Biosciences;
Amersham, UK). Levels of PPARg and pCREB were detected using a rabbit
monoclonal anti-PPARg antibody and a rabbit monoclonal anti-pCREB anti-
body and normalized to actin expression using a polyclonal anti-b-actin
antibody (all at 1:1000 dilution). Subsequently, themembraneswere incubated
with the appropriate secondary antibodies coupled to horseradish peroxidase
(1:10000 dilution), and the bands were visualized using chemiluminescence
(Amersham Biosciences) on a BioRad Fluomax gel imaging system.
Adenylyl Cyclase Measurements
Measurements of adenylyl cyclase activity were performed as described (Mer-
kouris et al., 1997). The cells were cultured in poly-D-lysine-coated 12-well
plates and incubated in medium containing [3H]adenine (1.5 mCi/well) for
16 hr. Generation of [3H]cAMP in response to the treatment was assessed146 Cell Metabolism 10, 139–147, August 6, 2009 ª2009 Elsevier Inby chromatography. Results are presented as the ratio of levels of [3H]cAMP
to total [3H]adenine nucleotides.
Quantitative PCR
Cells and tissues were lysed using TRIzol reagent, and the RNAwas recovered
by precipitation with isopropyl alcohol. The pellet was washed with 70%
ethanol and suspended in DEPC-treated water. RNA was quantified using a
RiboGreen dye kit (Invitrogen), and complementary DNA (cDNA) was gener-
ated using the SuperScript III Reverse Transcriptase kit (Invitrogen). The
product was cleaned using a PCR purification kit (Invitrogen) and visualized
on a 1.5% agarose gel stained with SYBR green dye adjacent to a low-molec-
ular-weight ladder. Primers were designed using the Ensembl Genome
Browser and the Roche website (Roche; Burgess Hill, UK). Copies of the
primer and probe sequences are available from the authors on request. Levels
of gene expression were expressed as copy number per nanogram of total
RNA.
Bone Histomorphometry and Micro-CT Analysis
Bone histomorphometry was performed on the proximal tibial metaphysis. The
bones were fixed in 70% ethanol, decalcified in 10% EDTA, and embedded in
methyl-methacrylate using the Technovit 9100 kit (TAAB; Reading, UK) or in
wax sections, according to standard techniques. Sections were prepared
using a Leica microtome (1.5 mm thick for MMA and 5 mm thick for wax), and
bone histomorphometry was assessed using a semiautomated image analysis
system. Micro-CT analysis was performed at the left tibial metaphysis
(200 slices directly distal of the growth plate) using a SkyScan 1172 instrument
set at 60 kV and 150 mA, at a resolution of 5 mm. The images were recon-
structed using the SkyScan NRecon program and analyzed using SkyScan
CTAn software.
Biochemical Markers of Bone Turnover
Serum CTX (a marker of bone resorption) and P1NP (a marker of bone forma-
tion) were measured using mouse/rat competitive enzyme immunoassay kits
(IDS; Boldon, UK), according to the manufacturer’s instructions.
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